Incorporation of the B18R gene of vaccinia virus into an oncolytic herpes simplex virus improves antitumor activity

Molecular Therapy

Volumn 20, Issue 10, 2012, Pages 1871-1881

  Fu, Xinping ^a   Rivera, Armando ^a   Tao, Lihua ^a   Zhang, Xiaoliu ^a  

^a University of Houston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE RECEPTOR; DECOY RECEPTOR; INTERFERON; ONCOLYTIC HERPES VIRUS; ONCOLYTIC HERPES VIRUS SYNCO 2D; ONCOLYTIC HERPES VIRUS SYNCO B18R; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B18R GENE; CANCER SIZE; FEMALE; GENE INSERTION; GENETIC ENGINEERING; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LIVER CELL CARCINOMA; MOLECULAR CLONING; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; VACCINIA VIRUS; VIRUS GENE; VIRUS REPLICATION; VIRUS STRAIN;

HUMAN HERPESVIRUS 1; SIMPLEXVIRUS; VACCINIA VIRUS;

EID: 84867022259     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.113     Document Type: Article

References (47)

1. Kelly, E and Russell, SJ (2007). History of oncolytic viruses: genesis to genetic engineering. Mol Ther 15: 651-659.
2. Vähä-Koskela, MJ, Heikkilä, JE and Hinkkanen, AE (2007). Oncolytic viruses in cancer therapy. Cancer Lett 254: 178-216.
3. Prestwich, RJ, Errington, F, Diaz, RM, Pandha, HS, Harrington, KJ, Melcher, AA et al. (2009). The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther 20: 1119-1132.
4. Stanford, MM, Breitbach, CJ, Bell, JC and McFadden, G (2008). Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes? Curr Opin Mol Ther 10: 32-37.
5. Parato, KA, Lichty, BD and Bell, JC (2009). Diplomatic immunity: turning a foe into an ally. Curr Opin Mol Ther 11: 13-21.
6. Chiocca, EA (2008). The host response to cancer virotherapy. Curr Opin Mol Ther 10: 38-45.
7. Zuniga, EI, Hahm, B and Oldstone, MB (2007). Type I interferon during viral infections: multiple triggers for a multifunctional mediator. Curr Top Microbiol Immunol 316: 337-357.
8. McInerney, GM and Karlsson Hedestam, GB (2009). Direct cleavage, proteasomal degradation and sequestration: three mechanisms of viral subversion of type I interferon responses. J Innate Immun 1: 599-606.
9. Paladino, P and Mossman, KL (2009). Mechanisms employed by herpes simplex virus 1 to inhibit the interferon response. J Interferon Cytokine Res 29: 599-607.
10. Paladino, P, Collins, SE and Mossman, KL (2010). Cellular localization of the herpes simplex virus ICP0 protein dictates its ability to block IRF3-mediated innate immune responses. PLoS ONE 5: e10428.
11. Johnson, KE, Song, B and Knipe, DM (2008). Role for herpes simplex virus 1 ICP27 in the inhibition of type I interferon signaling. Virology 374: 487-494.
12. Mulvey, M, Camarena, V and Mohr, I (2004). Full resistance of herpes simplex virus type 1-infected primary human cells to alpha interferon requires both the Us11 and gamma(1)34.5 gene products. J Virol 78: 10193-10196.
13. Sànchez, R and Mohr, I (2007). Inhibition of cellular 2'-5' oligoadenylate synthetase by the herpes simplex virus type 1 Us11 protein. J Virol 81: 3455-3464.
14. Perdiguero, B and Esteban, M (2009). The interferon system and vaccinia virus evasion mechanisms. J Interferon Cytokine Res 29: 581-598.
15. Symons, JA, Alcamí, A and Smith, GL (1995). Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specifcity. Cell 81: 551-560.
16. Colamonici, OR, Domanski, P, Sweitzer, SM, Larner, A and Buller, RM (1995). Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling. J Biol Chem 270: 15974-15978.
17. Conrady, CD, Halford, WP and Carr, DJ (2011). Loss of the type I interferon pathway increases vulnerability of mice to genital herpes simplex virus 2 infection. J Virol 85: 1625-1633.
18. Carr, DJ, Al-khatib, K, James, CM and Silverman, R (2003). Interferon-beta suppresses herpes simplex virus type 1 replication in trigeminal ganglion cells through an RNase L-dependent pathway. J Neuroimmunol 141: 40-46.
19. Sainz, B Jr and Halford, WP (2002). Alpha/Beta interferon and gamma interferon synergize to inhibit the replication of herpes simplex virus type 1. J Virol 76: 11541-11550.
20. Casrouge, A, Zhang, SY, Eidenschenk, C, Jouanguy, E, Puel, A, Yang, K et al. (2006). Herpes simplex virus encephalitis in human UNC-93B defciency. Science 314: 308-312.
21. Nakamori, M, Fu, X, Meng, F, Jin, A, Tao, L, Bast, RCJ et al. (2003). Effective Therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane-fusion mechanisms. Clin Cancer Res 9: 2727-2733.
22. Fu, X, Meng, F, Tao, L, Jin, A and Zhang, X (2003). A strict-late viral promoter is a strong tumor-specifc promoter in the context of an oncolytic herpes simplex virus. Gene Ther 10: 1458-1464.
23. Fu, X, Tao, L, Jin, A, Vile, R, Brenner, M and Zhang, X (2003). Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus provides potent synergistic anti-tumor effect. Mol Ther 7: 748-754.
24. Nakamori, M, Fu, X, Pettaway, CA and Zhang, X (2004). Potent antitumor activity after systemic delivery of a doubly fusogenic oncolytic herpes simplex virus against metastatic prostate cancer. Prostate 60: 53-60.
25. Schellingerhout, D, Bogdanov, A Jr, Marecos, E, Spear, M, Breakefeld, X and Weissleder, R (1998). Mapping the in vivo distribution of herpes simplex virions. Hum Gene Ther 9: 1543-1549.
26. Ulbricht, A, Färber, I and Wutzler, P (1985). Herpes simplex virus hepatitis in mice: effects of treatment with trisodium phosphonoformate. Acta Virol 29: 493-498.
27. Goodman, ZD, Ishak, KG and Sesterhenn, IA (1986). Herpes simplex hepatitis in apparently immunocompetent adults. Am J Clin Pathol 85: 694-699.
28. Todo, T, Rabkin, SD and Martuza, RL (2000). Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors. Cancer Gene Ther 7: 939-946.
29. Leveille, S, Samuel, S, Goulet, ML and Hiscott, J (2011). Enhancing VSV oncolytic activity with an improved cytosine deaminase suicide gene strategy. Cancer Gene Ther 18: 435-443.
30. Foloppe, J, Kintz, J, Futin, N, Findeli, A, Cordier, P, Schlesinger, Y et al. (2008). Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus. Gene Ther 15: 1361-1371.
31. Simpson, GR, Han, Z, Liu, B, Wang, Y, Campbell, G and Coffn, RS (2006). Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control. Cancer Res 66: 4835-4842.
32. Kim, JH, Lee, YS, Kim, H, Huang, JH, Yoon, AR and Yun, CO (2006). Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and effcacy. J Natl Cancer Inst 98: 1482-1493.
33. McKee, TD, Grandi, P, Mok, W, Alexandrakis, G, Insin, N, Zimmer, JP et al. (2006). Degradation of fbrillar collagen in a human melanoma xenograft improves the effcacy of an oncolytic herpes simplex virus vector. Cancer Res 66: 2509-2513.
34. Hong, CS, Fellows, W, Niranjan, A, Alber, S, Watkins, S, Cohen, JB et al. (2010). Ectopic matrix metalloproteinase-9 expression in human brain tumor cells enhances oncolytic HSV vector infection. Gene Ther 17: 1200-1205.
35. Fulci, G, Breymann, L, Gianni, D, Kurozomi, K, Rhee, SS, Yu, J et al. (2006). Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci USA 103: 12873-12878.
36. Li, H, Zeng, Z, Fu, X and Zhang, X (2007). Coadministration of a herpes simplex virus-2 based oncolytic virus and cyclophosphamide produces a synergistic antitumor effect and enhances tumor-specifc immune responses. Cancer Res 67: 7850-7855.
37. Otsuki, A, Patel, A, Kasai, K, Suzuki, M, Kurozumi, K, Chiocca, EA et al. (2008). Histone deacetylase inhibitors augment antitumor effcacy of herpes-based oncolytic viruses. Mol Ther 16: 1546-1555.
38. Ikeda, K, Wakimoto, H, Ichikawa, T, Jhung, S, Hochberg, FH, Louis, DN et al. (2000). Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J Virol 74: 4765-4775.
39. Wakimoto, H, Johnson, PR, Knipe, DM and Chiocca, EA (2003). Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Ther 10: 983-990.
40. Fulci, G, Dmitrieva, N, Gianni, D, Fontana, EJ, Pan, X, Lu, Y et al. (2007). Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res 67: 9398-9406.
41. Pierce, AT, DeSalvo, J, Foster, T P, Kosinski, A, Weller, SK and Halford, WP (2005). Beta interferon and gamma interferon synergize to block viral DNA and virion synthesis in herpes simplex virus-infected cells. J Gen Virol 86(Pt 9): 2421-2432.
42. Siegal, FP, Kadowaki, N, Shodell, M, Fitzgerald-Bocarsly, PA, Shah, K, Ho, S et al. (1999). The nature of the principal type 1 interferon-producing cells in human blood. Science 284: 1835-1837.
43. Spear, PG (2004). Herpes simplex virus: receptors and ligands for cell entry. Cell Microbiol 6: 401-410.
44. Li, W, Ding, F, Zhang, L, Liu, Z, Wu, Y, Luo, A et al. (2005). Overexpression of stefn A in human esophageal squamous cell carcinoma cells inhibits tumor cell growth, angiogenesis, invasion, and metastasis. Clin Cancer Res 11(24 Pt 1): 8753-8762.
45. Fu, X, Tao, L, Rivera, A, Xu, H and Zhang, X (2011). Virotherapy induces massive infltration of neutrophils in a subset of tumors defned by a strong endogenous interferon response activity. Cancer Gene Ther 18: 785-794.
46. Fu, X, Tao, L, Rivera, A, Williamson, S, Song, XT, Ahmed, N et al. (2010). A simple and sensitive method for measuring tumor-specifc T cell cytotoxicity. PLoS ONE 5: e11867.
47. Fu, X, Rivera, A, Tao, L, De Geest, B and Zhang, X (2012). Construction of an oncolytic herpes simplex virus that precisely targets hepatocellular carcinoma cells. Mol Ther 20: 339-346.